Published in Lab Business Week, November 7th, 2004
These results suggest replacing leucovorin, the currently used adjunctive agent, with CoFactor in humans could reduce the side effects associated with using 5-FU while simultaneously improving 5-FU's antitumor activity. Results were presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics conference in Geneva, Switzerland on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.